Ersodetug clinical trials
How each study uses ersodetug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ersodetug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Ersodetug
- 1
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
Rezolute (3) · XOMA (US) LLC (1)
Often tested with
Tested in the same studies.
XOMA 358 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test ersodetug, phase 3 first.
- Sep 2027A Phase 3 Study of Ersodetug in Patients With Tumor HyperinsulinismPhase 3 · Rezolute
Studies
Open first, then newest update. How each study uses ersodetug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 3 Study of Ersodetug in Patients With Tumor HyperinsulinismRecruitingPhase 3RezoluteNCT06881992Written as Ersodetug
- RZ358 Treatment for Congenital HyperinsulinismActive, not recruitingPhase 3RezoluteNCT06208215Written as RZ358 (5-10 mg/kg) + SOC
- An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital HyperinsulinismCompletedPhase 2RezoluteNCT04538989Written as RZ358 Sequential Group Cohort 1
- An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass SurgeryCompletedPhase 2XOMA (US) LLCNCT02772718Written as XOMA 358 single dose level A
Codes
What other systems call ersodetug · ClinicalTrials.gg INT017678
- UNII (FDA) QD87BSP58NERSODETUGOne source FDA
- NCI Thesaurus C199043ErsodetugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QD87BSP58N | ERSODETUG | One source FDA |
| NCI Thesaurus | C199043 | Ersodetug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.